FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

펩타이드 라이브러리

Snap-8

Acetyl Octapeptide-3 / SNAP-8 Peptide

Beauty & Skincare

SNAP-8 (Acetyl Octapeptide-3, also marketed as Acetyl Glutamyl Heptapeptide-1) is a topical cosmetic peptide consisting of eight amino acids that modulates the SNARE complex responsible for neurotransmitter release at the neuromuscular junction. Developed by Lipotec as an extension of the hexapeptide Argireline concept, SNAP-8 is marketed as a topical alternative to botulinum toxin for reducing expression lines and wrinkles. It competitively inhibits SNARE complex formation, theoretically reducing muscle contraction intensity and thereby diminishing dynamic wrinkles.

작용 메커니즘

Octapeptide that mimics the N-terminal of SNAP-25, a key protein in the SNARE complex responsible for neurotransmitter release at neuromuscular junctions. Competitively inhibits SNARE complex formation, reducing muscle contraction intensity and thereby reducing expression lines.

연구 프로토콜

연구 용도만 사용 가능. 의학적 조언은 아닙니다.

Topical application only. Used at 3-10% concentration in serums applied twice daily to expression-line areas (forehead, crow's feet, glabella). Not injected. Continuous use required for maintained effect.

연구 노트

Clinical Research Status

SNAP-8 has been evaluated in manufacturer-sponsored clinical studies showing wrinkle depth reduction of up to 63% after 28 days of regular application at concentrations of 3-10% in cream formulations. Independent peer-reviewed clinical data is limited compared to manufacturer claims, with most published evidence coming from in vitro SNARE complex inhibition assays rather than controlled clinical trials. It is widely available in cosmetic formulations globally and does not require regulatory approval for topical cosmetic use.

Key Published Findings

In vitro studies demonstrate that SNAP-8 inhibits SNARE complex assembly by competing with SNAP-25 (Synaptosomal-Associated Protein of 25 kDa) for incorporation into the exocytosis machinery. Catecholamine release assays in chromaffin cells show dose-dependent reduction in vesicular fusion and neurotransmitter release at relevant peptide concentrations. The eight-amino acid sequence provides enhanced stability and potentially greater SNARE complex affinity compared to the shorter six-amino acid Argireline sequence.

Safety Profile

SNAP-8 has an excellent safety profile for topical application, with no systemic absorption concerns at cosmetic concentrations and no reported sensitization or irritation in patch testing studies. Unlike injectable botulinum toxin, topical SNAP-8 cannot produce muscle paralysis, ptosis, or other serious adverse effects associated with neuromuscular blockade. It is considered suitable for sensitive skin and periorbital use, with no reported phototoxicity or photoallergic reactions.

Comparison to Related Compounds

SNAP-8 is an elongated version of Argireline (Acetyl Hexapeptide-3), with two additional amino acids theoretically providing greater potency and stability in SNARE complex inhibition. Both peptides target the same mechanism but cannot replicate the complete muscle paralysis achieved by botulinum toxin injection, offering instead a modest reduction in muscle contraction intensity. Compared to Matrixyl which stimulates collagen production, SNAP-8 addresses a completely different aspect of aging (dynamic wrinkles vs. structural collagen loss) and the two are complementary in formulations.

Community Observations

Skincare communities generally report subtle but noticeable improvements in forehead lines and crow's feet with consistent use over 4-8 weeks. Users frequently note that SNAP-8 works best as part of a comprehensive anti-aging routine rather than as a standalone treatment, managing expectations relative to injectable alternatives. DIY skincare formulators commonly work with SNAP-8 solutions at 3-10% concentration, noting that higher concentrations do not necessarily produce proportionally better results.

반감기

N/A (topical)

재조성

N/A (topical formulation)

보관

건조한 상태

Room temperature. Protect from light.

재조성된 상태

Store at room temperature. Stable in formulation for 12+ months.

미국 법적 상태

Cosmetic ingredient (unregulated)

또는 알려진 이름으로

Acetyl Octapeptide-3SNAP-8 Peptide

자주 묻는 질문

Snap-8란 무엇인가요?

SNAP-8 (Acetyl Octapeptide-3, also marketed as Acetyl Glutamyl Heptapeptide-1) is a topical cosmetic peptide consisting of eight amino acids that modulates the SNARE complex responsible for neurotransmitter release at the neuromuscular junction. Developed by Lipotec as an extension of the hexapeptide Argireline concept, SNAP-8 is marketed as a topical alternative to botulinum toxin for reducing expression lines and wrinkles. It competitively inhibits SNARE complex formation, theoretically reducing muscle contraction intensity and thereby diminishing dynamic wrinkles.

Snap-8는 어떻게 작용하나요?

Octapeptide that mimics the N-terminal of SNAP-25, a key protein in the SNARE complex responsible for neurotransmitter release at neuromuscular junctions. Competitively inhibits SNARE complex formation, reducing muscle contraction intensity and thereby reducing expression lines.

Snap-8의 미국 규제 현황은 어떤가요?

Cosmetic ingredient (unregulated)

Snap-8의 반감기는 얼마인가요?

N/A (topical)

Snap-8의 다른 이름은 무엇인가요?

Acetyl Octapeptide-3, SNAP-8 Peptide

Peptide Contacts는 정보 제공을 위해 연구 기반 요약을 제공합니다. 우리는 공급업체 문서를 호스팅, 배포하거나 지지하지 않습니다. 모든 테스트 보고서, GMP 인증서 및 공급업체 통신은 구매자는 직접 요청하고 확인해야 합니다. 이 플랫폼에서 제공되는 어떠한 정보도 법적, 의학적 또는 전문적인 조언을 대체하지 않습니다. 사용자는 모든 관련 지역법, 주법 및 연방법에 부합하기 위해 공급업체 자격 증명을 검증하고 구매하기 전에 준수해야 합니다. 이 플랫폼의 사용은 이러한 책임을 완전히 지닌 것으로 간주됩니다.

전체 공지사항 읽기